In conclusion, we found that free-living use of hybrid closed-loop insulin delivery over a period of 12 weeks led to clinically meaningful improvements in glycaemic control, while reducing the risk of hypoglycaemia in suboptimally controlled type 1 diabetes in adults, adolescents, and children aged 6 years and older. This evidence concerns the gene INS and Hypoglycemia.